Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) Return on Sales (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Return on Sales for 3 consecutive years, with 100.83% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 57948.0% to 100.83% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 100.83% through Dec 2025, up 31364.0% year-over-year, with the annual reading at 107.73% for FY2025, 854559.0% down from the prior year.
  • Return on Sales for Q4 2025 was 100.83% at Inhibrx Biosciences, down from 120.31% in the prior quarter.
  • The five-year high for Return on Sales was 18580.11% in Q2 2024, with the low at 1568.4% in Q2 2023.
  • Average Return on Sales over 3 years is 1455.41%, with a median of 22.04% recorded in 2025.
  • The sharpest move saw Return on Sales surged 2014851bps in 2024, then crashed -1860215bps in 2025.
  • Over 3 years, Return on Sales stood at 56.29% in 2023, then crashed by -750bps to 478.65% in 2024, then skyrocketed by 121bps to 100.83% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 100.83%, 120.31%, and 22.04% for Q4 2025, Q3 2025, and Q2 2025 respectively.